Related Experiment Video
Updated: Aug 20, 2026
Robust Comparison of Protein Levels Across Tissues and Throughout Development Using Standardized Quantitative Western Blotting
Published on: April 9, 2019
Newborn screening for fragile X syndrome
1Frank Porter Graham Child Development Institute, CB # 8180, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. don_bailey@unc.edu
Insights
Newborn screening for fragile X syndrome (FXS) is becoming technically feasible. This article examines the potential adoption of FXS newborn screening by public health systems, considering benefits and challenges.
Area of Science:
- Genetics
- Public Health Policy
- Medical Screening
Background:
- Fragile X syndrome (FXS) is a genetic disorder with potential for early intervention.
- Newborn screening policies have evolved, with technological advancements enabling broader application.
- The feasibility of newborn screening for FXS is increasing with improved technologies.
Purpose of the Study:
- To evaluate the likelihood of the US public health system adopting newborn screening for fragile X syndrome.
- To contextualize FXS screening within the history and current practices of newborn screening.
- To explore arguments for and against implementing FXS newborn screening.
Main Methods:
- Historical analysis of newborn screening policies.
- Discussion of current newborn screening practices.
- Argumentation based on potential benefits and barriers to screening.
Main Results:
- Technically, newborn screening for FXS is achievable.
- Inexpensive and accurate screening technologies are anticipated in the near future.
- Potential barriers include the lack of a definitive medical treatment for FXS.
Conclusions:
- Early intervention services offer significant benefits to infants identified with FXS and their families.
- Arguments such as informed reproductive risk, medically necessary information, and consumer demand support FXS newborn screening.
- FXS serves as a model for addressing broader societal issues related to genetic disorder discovery and screening technologies.
Abstract:
Newborn screening for fragile X syndrome (FXS) is technically possible, and in the relatively near future accurate and inexpensive screening technologies are likely to be available. When that happens, will America's public health system adopt newborn screening for fragile X syndrome? This article addresses this issue by first placing screening for FXS in the context of the history and current status of newborn screening policy and practice. Lack of a proven medical treatment may stand as a barrier to newborn screening, but strong arguments can be made that early intervention provides important services for identified newborns and their families. Furthermore, other arguments could be used to justify newborn screening, including informed reproductive risk, medically necessary information, and consumer demand. Fragile X syndrome is offered as a prototype for many of the issues that will face society as more genetic disorders are discovered and new technologies for screening are developed.
More Related Videos
08:22A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
Published on: September 16, 2019
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Related Concept Videos
01:43Sex-linked Disorders
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...